ES2177112T3 - Agentes angiostaticos y composiciones para tratar el glaucoma glc1a. - Google Patents

Agentes angiostaticos y composiciones para tratar el glaucoma glc1a.

Info

Publication number
ES2177112T3
ES2177112T3 ES98961956T ES98961956T ES2177112T3 ES 2177112 T3 ES2177112 T3 ES 2177112T3 ES 98961956 T ES98961956 T ES 98961956T ES 98961956 T ES98961956 T ES 98961956T ES 2177112 T3 ES2177112 T3 ES 2177112T3
Authority
ES
Spain
Prior art keywords
compositions
glc1a
treat glaucoma
angiostatic agents
angiostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98961956T
Other languages
English (en)
Inventor
Abbot F Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of ES2177112T3 publication Critical patent/ES2177112T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Abstract

El uso de un agente angiostático para la fabricación de un medicamento para el tratamiento del glaucoma GLC1A.
ES98961956T 1997-12-19 1998-12-07 Agentes angiostaticos y composiciones para tratar el glaucoma glc1a. Expired - Lifetime ES2177112T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/994,114 US5990099A (en) 1988-10-31 1997-12-19 Angiostatic agents and methods and compositions for controlling ocular hypertension

Publications (1)

Publication Number Publication Date
ES2177112T3 true ES2177112T3 (es) 2002-12-01

Family

ID=25540297

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98961956T Expired - Lifetime ES2177112T3 (es) 1997-12-19 1998-12-07 Agentes angiostaticos y composiciones para tratar el glaucoma glc1a.

Country Status (13)

Country Link
US (1) US5990099A (es)
EP (1) EP1039912B1 (es)
JP (1) JP2001526233A (es)
AT (1) ATE221781T1 (es)
AU (1) AU734436B2 (es)
BR (1) BR9813684A (es)
CA (1) CA2315829C (es)
DE (1) DE69807115T2 (es)
DK (1) DK1039912T3 (es)
ES (1) ES2177112T3 (es)
HK (1) HK1029922A1 (es)
PT (1) PT1039912E (es)
WO (1) WO1999032127A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1935501A (en) * 1999-12-09 2001-06-18 Alcon Universal Limited Id protein inhibitors for treating ocular diseases
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
US8679089B2 (en) * 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
DE60131273T2 (de) 2000-05-19 2008-08-28 Michael S. Beverly Hills Berlin Laserapplikationssystem und methode zur verwendung im auge
US7402577B2 (en) * 2001-10-03 2008-07-22 Merck & Co., Inc. Androstane 17-beta-carboxamides as androgen receptor modulators
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
US7579335B2 (en) 2005-01-10 2009-08-25 Glaxo Group Limited Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
CN103169714A (zh) * 2005-07-12 2013-06-26 Dmi生物科学公司 治疗疾病的方法和产品
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US8267882B2 (en) 2008-03-05 2012-09-18 Ivantis, Inc. Methods and apparatus for treating glaucoma
ES2548138T3 (es) 2008-05-28 2015-10-14 Reveragen Biopharma, Inc. Moduladores esteroideos no hormonales de NF-kappaB para el tratamiento de enfermedades
BRPI1010086A2 (pt) * 2009-06-22 2018-02-06 Dmi Acquisition Corp método e produtos para tratamento de doenças
KR101877041B1 (ko) 2009-06-22 2018-07-10 앰피오 파마슈티컬스 인코퍼레이티드 혈관 과투과성과 부종 및 이로부터 발생하는 다른 부작용을 저해하는 방법
JP5635605B2 (ja) 2009-07-09 2014-12-03 イバンティス インコーポレイテッド 眼内インプラント及び眼内インプラントを眼球内に送出するための方法
CN102481171B (zh) 2009-07-09 2015-01-28 伊万提斯公司 用于输送眼部植入物的单人操作装置
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
BR112015014261A8 (pt) 2012-12-19 2019-10-08 Ampio Pharmaceuticals Inc composto de danazol, seu uso e formulação farmacêutica compreendendo este
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
JP6837475B2 (ja) 2015-08-14 2021-03-03 イバンティス インコーポレイテッド 圧力センサを備えた眼用インプラントおよび送達システム
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
US11540940B2 (en) 2021-01-11 2023-01-03 Alcon Inc. Systems and methods for viscoelastic delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642355A (en) * 1984-02-24 1987-02-10 Otsuka Pharmaceutical Factory, Inc. Proline derivatives
US4863912A (en) * 1986-05-19 1989-09-05 New York Medical College Use of tetrahydrocortisol in glaucoma therapy
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
WO1991019731A1 (en) * 1990-06-11 1991-12-26 The Upjohn Company Steroids which inhibit angiogenesis
EP1236471A3 (en) * 1991-11-22 2004-12-15 Alcon Laboratories, Inc. Angiostatic steroids
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5606043A (en) * 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma

Also Published As

Publication number Publication date
DE69807115D1 (de) 2002-09-12
AU734436B2 (en) 2001-06-14
EP1039912A1 (en) 2000-10-04
DE69807115T2 (de) 2002-12-12
BR9813684A (pt) 2000-10-10
HK1029922A1 (en) 2001-04-20
PT1039912E (pt) 2002-12-31
DK1039912T3 (da) 2002-10-28
US5990099A (en) 1999-11-23
AU1714299A (en) 1999-07-12
CA2315829A1 (en) 1999-07-01
EP1039912B1 (en) 2002-08-07
WO1999032127A1 (en) 1999-07-01
CA2315829C (en) 2009-05-12
ATE221781T1 (de) 2002-08-15
JP2001526233A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
ES2177112T3 (es) Agentes angiostaticos y composiciones para tratar el glaucoma glc1a.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
ATE228015T1 (de) Intestinale absorption von nikotin für die behandlung von nikotinabhängigen zustanden
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
GT199700074A (es) Derivados de 2-(2-oxo-etiliden)-imidazolidin-4-ona
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
MX9302011A (es) Derivados de indol.
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE327973T1 (de) Polyamin-analoge als cytotoxische wirkstoffe
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
PT1109814E (pt) 5-heterociclil pirazol¬4,3-d|pirimidina-7-onas para o tratamento da disfuncao erectil masculina
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
BR9809848A (pt) Composição
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
PT1294732E (pt) Compostos de rutenio (ii) para utilizacao na terapia do cancro
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
HK1039568A1 (en) Use of ap-1 activators to treat glaucoma and ocular hypertension.
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
PA8435701A1 (es) Composiciones y metodos farmaceuticos para el tratamiento de una anormalidad en el glutamato y que producen una actividad neuronal en el animal utilizando los inhibidores de la naala